Literature DB >> 25292427

Eph receptors and ephrins: therapeutic opportunities.

Antonio Barquilla1, Elena B Pasquale.   

Abstract

The erythropoietin-producing hepatocellular carcinoma (Eph) receptor tyrosine kinase family plays important roles in developmental processes, adult tissue homeostasis, and various diseases. Interaction with Eph receptor-interacting protein (ephrin) ligands on the surface of neighboring cells triggers Eph receptor kinase-dependent signaling. The ephrins can also transmit signals, leading to bidirectional cell contact-dependent communication. Moreover, Eph receptors and ephrins can function independently of each other through interplay with other signaling systems. Given their involvement in many pathological conditions ranging from neurological disorders to cancer and viral infections, Eph receptors and ephrins are increasingly recognized as attractive therapeutic targets, and various strategies are being explored to modulate their expression and function. Eph receptor/ephrin upregulation in cancer cells, the angiogenic vasculature, and injured or diseased tissues also offer opportunities for Eph/ephrin-based targeted drug delivery and imaging. Thus, despite the challenges presented by the complex biology of the Eph receptor/ephrin system, exciting possibilities exist for therapies exploiting these molecules.

Entities:  

Keywords:  angiogenesis; cancer; neurological disease; tyrosine kinase; viral infection

Mesh:

Substances:

Year:  2014        PMID: 25292427      PMCID: PMC4388660          DOI: 10.1146/annurev-pharmtox-011112-140226

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  172 in total

Review 1.  EphA2-dependent molecular targeting therapy for malignant tumors.

Authors:  Rong Biao-xue; Cai Xi-guang; Yang Shuan-ying; Li Wei; Ming Zong-juan
Journal:  Curr Cancer Drug Targets       Date:  2011-11       Impact factor: 3.428

Review 2.  Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis.

Authors:  Ombretta Salvucci; Giovanna Tosato
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

3.  EphB signaling inhibits gap junctional intercellular communication and synchronized contraction in cultured cardiomyocytes.

Authors:  Maki Ishii; Itsuki Mueller; Takayuki Nakajima; Elena B Pasquale; Kazushige Ogawa
Journal:  Basic Res Cardiol       Date:  2011-09-03       Impact factor: 17.165

4.  Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.

Authors:  Pierre Saintigny; Shaohua Peng; Li Zhang; Banibrata Sen; Ignacio I Wistuba; Scott M Lippman; Luc Girard; John D Minna; John V Heymach; Faye M Johnson
Journal:  Mol Cancer Ther       Date:  2012-07-17       Impact factor: 6.261

5.  Ephrin Bs are essential components of the Reelin pathway to regulate neuronal migration.

Authors:  Aycan Sentürk; Sylvia Pfennig; Alexander Weiss; Katja Burk; Amparo Acker-Palmer
Journal:  Nature       Date:  2011-04-03       Impact factor: 49.962

Review 6.  Therapeutic perspectives of Eph-ephrin system modulation.

Authors:  Massimiliano Tognolini; Iftiin Hassan-Mohamed; Carmine Giorgio; Ilaria Zanotti; Alessio Lodola
Journal:  Drug Discov Today       Date:  2013-11-26       Impact factor: 7.851

7.  A role for ephrin-A5 in axonal sprouting, recovery, and activity-dependent plasticity after stroke.

Authors:  Justine J Overman; Andrew N Clarkson; Ina B Wanner; William T Overman; Ilya Eckstein; Jaime L Maguire; Ivo D Dinov; Arthur W Toga; S Thomas Carmichael
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-25       Impact factor: 11.205

8.  Dual-modality micro-positron emission tomography/computed tomography and near-infrared fluorescence imaging of EphB4 in orthotopic glioblastoma xenograft models.

Authors:  Miao Huang; Chiyi Xiong; Wei Lu; Rui Zhang; Min Zhou; Qian Huang; Jeffrey Weinberg; Chun Li
Journal:  Mol Imaging Biol       Date:  2014-02       Impact factor: 3.488

9.  Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.

Authors:  Elizabeth M Bruckheimer; Christine A Fazenbaker; Sandra Gallagher; Kathy Mulgrew; Stacy Fuhrmann; Karen T Coffman; William Walsh; Shannon Ready; Kim Cook; Melissa Damschroder; Michael Kinch; Peter A Kiener; Rob Woods; Changshou Gao; William Dall'Acqua; Herren Wu; Steven Coats
Journal:  Neoplasia       Date:  2009-06       Impact factor: 5.715

10.  The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.

Authors:  Benjamin D Ferguson; Ren Liu; Cleo E Rolle; Yi-Hung Carol Tan; Valery Krasnoperov; Rajani Kanteti; Maria S Tretiakova; Gustavo M Cervantes; Rifat Hasina; Robyn D Hseu; A John Iafrate; Theodore Karrison; Mark K Ferguson; Aliya N Husain; Leonardo Faoro; Everett E Vokes; Parkash S Gill; Ravi Salgia
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

View more
  110 in total

Review 1.  Mechanisms of ephrin-Eph signalling in development, physiology and disease.

Authors:  Artur Kania; Rüdiger Klein
Journal:  Nat Rev Mol Cell Biol       Date:  2016-01-21       Impact factor: 94.444

Review 2.  Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Authors:  Noam Pondé; Philippe Aftimos; Martine Piccart
Journal:  Curr Treat Options Oncol       Date:  2019-04-01

3.  EphA2 Transmembrane Domain Is Uniquely Required for Keratinocyte Migration by Regulating Ephrin-A1 Levels.

Authors:  Rosa Ventrella; Nihal Kaplan; Paul Hoover; Bethany E Perez White; Robert M Lavker; Spiro Getsios
Journal:  J Invest Dermatol       Date:  2018-04-26       Impact factor: 8.551

4.  KSR1 and EPHB4 Regulate Myc and PGC1β To Promote Survival of Human Colon Tumors.

Authors:  Jamie L McCall; Drew Gehring; Beth K Clymer; Kurt W Fisher; Binita Das; David L Kelly; Hyunseok Kim; Michael A White; Robert E Lewis
Journal:  Mol Cell Biol       Date:  2016-08-12       Impact factor: 4.272

Review 5.  Ephrin ligands and Eph receptors contribution to hematopoiesis.

Authors:  Giovanna Tosato
Journal:  Cell Mol Life Sci       Date:  2017-06-06       Impact factor: 9.261

6.  The SAM domain inhibits EphA2 interactions in the plasma membrane.

Authors:  Deo R Singh; Fozia Ahmed; Michael D Paul; Manasee Gedam; Elena B Pasquale; Kalina Hristova
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2016-10-21       Impact factor: 4.739

Review 7.  EphB4: A promising target for upper aerodigestive malignancies.

Authors:  Ravi Salgia; Prakash Kulkarni; Prakash S Gill
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-01-31       Impact factor: 10.680

8.  Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor To Achieve High Plasma Stability.

Authors:  Erika J Olson; Bernhard C Lechtenberg; Chunxia Zhao; Elena Rubio de la Torre; Ilaria Lamberto; Stefan J Riedl; Philip E Dawson; Elena B Pasquale
Journal:  ACS Med Chem Lett       Date:  2016-06-25       Impact factor: 4.345

Review 9.  Exploiting receptor tyrosine kinase co-activation for cancer therapy.

Authors:  Aik-Choon Tan; Simon Vyse; Paul H Huang
Journal:  Drug Discov Today       Date:  2016-07-21       Impact factor: 7.851

10.  Phosphorylation of PLCγ1 by EphA2 Receptor Tyrosine Kinase Promotes Tumor Growth in Lung Cancer.

Authors:  Wenqiang Song; Laura C Kim; Wei Han; Yuan Hou; Deanna N Edwards; Shan Wang; Timothy S Blackwell; Feixiong Cheng; Dana M Brantley-Sieders; Jin Chen
Journal:  Mol Cancer Res       Date:  2020-08-04       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.